Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois. The company produces pharmaceuticals for sale outside the United States (13% of 2024 revenues), diagnostic products (20% of 2024 revenues), nutritional products (22% of 2024 revenues), and medical devices (45% of 2024 revenues).
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 2025-10-16 22:07:50 | 127.57 | -0.06 | -0.05 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ABT | 0000001800 | ABBOTT LABORATORIES | US0028241000 | 549300JBDVIIMW4FW262 | 360698440 | NYSE | 2834 | Pharmaceutical Preparations | 1231 | IL | 100 ABBOTT PARK ROAD | ABBOTT PARK | IL | 60064-3500 | UNITED STATES | US | 2246676100 | 100 ABBOTT PARK ROAD, ABBOTT PARK, IL, 60064-3500 | 100 ABBOTT PARK ROAD, ABBOTT PARK, IL, 60064-3500 | — | Health care | 1888 | Robert B. Ford | 114,000 | http://abbott.com | 177,073,983,959 | 1,996,448,469 | 1,740,459,014 | Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois. The company produces pharmaceuticals for sale outside the United States (13% of 2024 revenues), diagnostic products (20% of 2024 revenues), nutritional products (22% of 2024 revenues), and medical devices (45% of 2024 revenues). | 2025-10-10 19:02:04 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2024 | 177,073,983,959 | -8,097,350,351 | -4.3729 | 1,734,323,411 | -860,878 | -0.0496 |
| 2023 | 185,171,334,310 | -933,711,880 | -0.5017 | 1,735,184,289 | -2,761,944 | -0.1589 |
| 2022 | 186,105,046,190 | -14,526,136,281 | -7.2402 | 1,737,946,233 | -25,536,034 | -1.448 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Hubert L. Allen | Secretary, Executive Vice President, General Counsel | 2024 | 911,154 | — | 2,095,365 | 1,094,700 | 540,170 | 7,981,335 |
| Lisa D. Earnhardt | Executive Vice President, Group President | 2024 | 879,269 | — | 2,016,528 | 1,249,200 | 130,047 | 6,558,461 |
| Robert B. Ford | Chief Executive Officer, Chairman Of The Board | 2024 | 1,500,000 | — | 8,226,593 | 2,861,250 | 618,998 | 22,777,075 |
| Philip P. Boudreau | Chief Financial Officer, Executive Vice President | 2024 | 884,039 | — | 2,693,071 | 1,224,700 | 74,748 | 8,225,746 |
| Daniel G. Salvadori | Executive Vice President, Group President | 2024 | 879,269 | — | 1,833,239 | 855,400 | 157,015 | 5,789,762 |
| Fiscal Year | Employee Count |
|---|---|
| 2024 | 114,000 |
| 2023 | 114,000 |
| 2022 | 115,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | 41,950,000,000 | 40,109,000,000 | 43,653,000,000 |
| Cost Of Revenue | 18,706,000,000 | 17,975,000,000 | 19,142,000,000 |
| Gross Profit | — | — | — |
| Research And Development Expenses | 2,844,000,000 | 2,741,000,000 | 2,888,000,000 |
| General And Administrative Expenses | 11,697,000,000 | 10,949,000,000 | 11,248,000,000 |
| Operating Expenses | 35,125,000,000 | 33,631,000,000 | 35,291,000,000 |
| Operating Income | 6,825,000,000 | 6,478,000,000 | 8,362,000,000 |
| Net Income | 13,402,000,000 | 5,723,000,000 | 6,933,000,000 |
| Earnings Per Share Basic | 7.67 | 3.28 | 3.94 |
| Earnings Per Share Diluted | 7.64 | 3.26 | 3.91 |
| Weighted Average Shares Outstanding Basic | 1,740,000,000 | 1,740,000,000 | 1,753,000,000 |
| Weighted Average Shares Outstanding Diluted | 1,748,000,000 | 1,749,000,000 | 1,764,000,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Cash And Cash Equivalents | 7,616,000,000 | 6,896,000,000 | 9,882,000,000 |
| Marketable Securities Current | 351,000,000 | 383,000,000 | 288,000,000 |
| Accounts Receivable | 6,925,000,000 | 6,565,000,000 | 6,218,000,000 |
| Inventories | 6,194,000,000 | 6,570,000,000 | 6,173,000,000 |
| Non Trade Receivables | — | — | — |
| Other Assets Current | — | — | — |
| Total Assets Current | 23,656,000,000 | 22,670,000,000 | 25,224,000,000 |
| Marketable Securities Non Current | 886,000,000 | 799,000,000 | 766,000,000 |
| Property Plant And Equipment | 10,658,000,000 | 10,154,000,000 | 9,162,000,000 |
| Other Assets Non Current | 784,000,000 | 787,000,000 | 807,000,000 |
| Total Assets Non Current | 18,500,000,000 | 16,200,000,000 | 14,200,000,000 |
| Total Assets | 81,414,000,000 | 73,214,000,000 | 74,438,000,000 |
| Accounts Payable | 4,195,000,000 | 4,295,000,000 | 4,607,000,000 |
| Deferred Revenue | — | — | — |
| Short Term Debt | 1,500,000,000 | 1,080,000,000 | 2,251,000,000 |
| Other Liabilities Current | 594,000,000 | 492,000,000 | 343,000,000 |
| Total Liabilities Current | 14,157,000,000 | 13,841,000,000 | 15,489,000,000 |
| Long Term Debt | 14,125,000,000 | 14,679,000,000 | 16,773,000,000 |
| Other Liabilities Non Current | 3,443,000,000 | 3,466,000,000 | 3,804,000,000 |
| Total Liabilities Non Current | — | — | — |
| Total Liabilities | — | — | — |
| Common Stock | 25,153,000,000 | 24,869,000,000 | 24,709,000,000 |
| Retained Earnings | 47,261,000,000 | 37,554,000,000 | 35,257,000,000 |
| Accumulated Other Comprehensive Income | -7,906,000,000 | -7,839,000,000 | -8,051,000,000 |
| Total Shareholders Equity | 47,664,000,000 | 38,603,000,000 | 36,686,000,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Depreciation And Amortization | 1,340,000,000 | 1,277,000,000 | 1,254,000,000 |
| Share Based Compensation Expense | 673,000,000 | 644,000,000 | 685,000,000 |
| Other Non Cash Income Expense | — | — | — |
| Change In Accounts Receivable | 691,000,000 | 356,000,000 | 68,000,000 |
| Change In Inventories | 58,000,000 | 232,000,000 | 1,413,000,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | — | — | — |
| Change In Accounts Payable | 356,000,000 | -760,000,000 | 420,000,000 |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | 8,558,000,000 | 7,261,000,000 | 9,581,000,000 |
| Purchases Of Marketable Securities | 169,000,000 | 159,000,000 | 185,000,000 |
| Sales Of Marketable Securities | — | — | — |
| Acquisition Of Property Plant And Equipment | 2,207,000,000 | 2,202,000,000 | 1,777,000,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | -9,000,000 | -22,000,000 | -22,000,000 |
| Cash From Investing Activities | -2,338,000,000 | -3,133,000,000 | -1,740,000,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | 3,904,000,000 | 3,625,000,000 | 3,365,000,000 |
| Issuance Of Common Stock | — | — | — |
| Repurchase Of Common Stock | 1,295,000,000 | 1,227,000,000 | 3,795,000,000 |
| Issuance Of Long Term Debt | — | — | — |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | — | — | 0 |
| Cash From Financing Activities | -5,404,000,000 | -7,091,000,000 | -7,636,000,000 |
| Change In Cash | 720,000,000 | -2,986,000,000 | 83,000,000 |
| Cash At End Of Period | 7,616,000,000 | 6,896,000,000 | 9,882,000,000 |
| Income Taxes Paid | 1,723,000,000 | 1,475,000,000 | 1,864,000,000 |
| Interest Paid | 604,000,000 | 662,000,000 | 563,000,000 |
| Fiscal Year | 2024 | 2023 | 2022 |
|---|---|---|---|
| Earnings Per Share | 7.67 | 3.28 | 3.94 |
| Price To Earnings Ratio | 14.7471 | 33.5579 | 27.8655 |
| Earnings Growth Rate | 133.8415 | -16.7513 | -0.7557 |
| Price Earnings To Growth Ratio | 0.1102 | -2.0033 | -36.8753 |
| Book Value Per Share | 38.6534 | 34.1224 | 33.6275 |
| Price To Book Ratio | 2.9263 | 3.2257 | 3.2649 |
| Ebitda | 17,024,000,000 | 9,112,000,000 | 10,609,000,000 |
| Enterprise Value | 204,820,400,000 | 200,384,800,000 | 201,603,870,000 |
| Dividend Yield | 0.0198 | 0.0189 | 0.0175 |
| Dividend Payout Ratio | 0.2913 | 0.6334 | 0.4854 |
| Debt To Equity Ratio | 0.3278 | 0.4082 | 0.5186 |
| Capital Expenditures | 1,844,000,000 | 2,269,000,000 | 1,457,000,000 |
| Free Cash Flow | 6,714,000,000 | 4,992,000,000 | 8,124,000,000 |
| Return On Equity | 0.2812 | 0.1483 | 0.189 |
| One Year Beta | 0.1988 | 0.5808 | 0.8336 |
| Three Year Beta | 0.6741 | 0.727 | 0.8273 |
| Five Year Beta | 0.762 | 0.8225 | 0.8681 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Gonzalez Patricia Paola | Director | 2025-09-30 | 246 | A | 4,922 |
| Roman Michael F | Director | 2025-09-30 | 281 | A | 5,556 |
| Alpern Robert J | Director | 2025-09-30 | 58 | A | 10,300 |
| Stratton John G | Director | 2025-09-30 | 293 | A | 12,663 |
| Boudreau Philip P | EVP AND CFO | 2025-09-01 | 387 | D | 50,616 |
| Name Of Reporting Person | Type Of Reporting Person | Report Date | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Shelley M Capito | Senator | 2025-03-06 | Sale (Partial) | 2025-02-24 | Spouse | $1,001 - $15,000 |
| Markwayne Mullin | Senator | 2025-01-31 | Sale (Full) | 2025-01-08 | Joint | $1,001 - $15,000 |
| Markwayne Mullin | Senator | 2024-12-31 | Sale (Partial) | 2024-12-11 | Joint | $15,001 - $50,000 |
| Thomas R Carper | Senator | 2024-02-02 | Sale (Partial) | 2024-01-17 | Spouse | $1,001 - $15,000 |
| Markwayne Mullin | Senator | 2023-11-01 | Purchase | 2023-10-03 | Joint | $1,001 - $15,000 |
| Name Of Reporting Person | Report Date | State | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Richard Dean Dr McCormick | 2025-09-17 | GA06 | Purchase | 2023-03-15 | — | $1,001 - $15,000 |
| Julie Johnson | 2025-09-11 | TX32 | Sale (Partial) | 2025-08-14 | Joint | $1,001 - $15,000 |
| Thomas H. Kean | 2025-08-20 | NJ07 | Purchase | 2025-07-21 | — | $1,001 - $15,000 |
| Lisa McClain | 2025-08-13 | MI09 | Purchase | 2025-06-24 | Spouse | $1,001 - $15,000 |
| Lisa McClain | 2025-08-13 | MI09 | Sale | 2025-07-10 | Spouse | $1,001 - $15,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| Enclave Advisors LLC | 2025-09-30 | 374,229 | 2,794 | 133.9402 |
| Andrew Hill Investment Advisors, Inc. | 2025-09-30 | 263,460 | 1,967 | 133.94 |
| Silver Lake Advisory, LLC | 2025-09-30 | 7,687,781 | 57,397 | 133.9405 |
| Kelly Financial Services LLC | 2025-09-30 | 252,888 | 1,888 | 133.9449 |
| Revisor Wealth Management LLC | 2025-09-30 | 490,747 | 3,683 | 133.2465 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| Jensen Quality Growth Fund Inc | 2025-08-31 | Y Shares | JENYX | 1,763,000 | 233,879,580 | 4.0349 |
| Jensen Quality Growth Fund Inc | 2025-08-31 | R Shares | JENRX | 1,763,000 | 233,879,580 | 4.0349 |
| Jensen Quality Growth Fund Inc | 2025-08-31 | I Shares | JENIX | 1,763,000 | 233,879,580 | 4.0349 |
| Jensen Quality Growth Fund Inc | 2025-08-31 | J Shares | JENSX | 1,763,000 | 233,879,580 | 4.0349 |
| NORTH COUNTRY FUNDS | 2025-08-31 | The North Country Large Cap Equity Fund | NCEGX | 13,000 | 1,724,580 | 1.3511 |